Previous 10 | Next 10 |
— Trial met primary endpoint of overall survival and all secondary endpoints — — Selected as a late-breaker presentation — — Conference call and webcast to be held on Monday, September 12 at 2:00 pm Paris time to review the prese...
Despite headwinds from inflation and geopolitical events, CK Hutchison showed good resilience with improvement results in the first half of this year. The dividend also got a bump of 5% for the interim period. With a solid balance sheet and a low valuation it looks tempting but th...
Hutchmed (China) ( NASDAQ: HCM ) and Inmagene Biopharmaceuticals said the first person based in the U.S. was dosed in a global phase 1 trial of IMG-004. Inmagene is developing IMG-004 to potentially treat immunological diseases. The study aims to eva...
SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals (" Inmagene ") and HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) announce today that the first participant, based in the Unite...
— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase III trial evaluating this combination is underway — HONG KONG and SHANGHAI, China and FLORHA...
Hutchmed (China) ( NASDAQ: HCM ) said its medicine fruquintinib met the main goal of overall survival (OS) in patients with advanced, refractory metastatic colorectal cancer (CRC) in a phase 3 trial. The study called FRESCO-2 evaluated fruquintinib plus be...
— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for regulatory submissions underway in the U.S., Europe and Japan ȁ...
HUTCHMED (China) Limited (HCM) Q2 2022 Earnings Conference Call August 02, 2022 08:00 AM ET Company Participants Weiguo Su - Executive Director, Chief Executive Officer and Chief Scientific Officer Johnny Cheng - Executive Director and Chief Financial Officer Mar...
HUTCHMED (China) Limited (HCM) Q2 2022 Earnings Conference Call August 02, 2022 08:00 AM ET Company Participants Christian Hogg - Chief Executive Officer Hong Chen - Senior Vice President and Chief Commercial Officer, China Weiguo Su - Executive Director and Chie...
The following slide deck was published by HUTCHMED (China) Limited in conjunction with their 2022 Q2 earnings call. For further details see: HUTCHMED (China) Limited 2022 Q2 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
HUTCHMED (China) Limited Company Name:
HCM Stock Symbol:
NASDAQ Market:
HUTCHMED (China) Limited Website:
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of adult pati...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylig...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a R&D update in Shanghai, China, and via webcast on Tuesday, July 9, 2024. During t...